医学
生活质量(医疗保健)
社会经济地位
内科学
伊布替尼
慢性淋巴细胞白血病
民族
白血病
老年学
环境卫生
人口
人类学
社会学
护理部
作者
Padma Youron,Charanpreet Singh,Nishant Jindal,Pankaj Malhotra,Alka Khadwal,Arihant Jain,Gaurav Prakash,Neelam Varma,Subhash Chander Varma,Deepesh Pravinkumar Lad
摘要
INTRODUCTION: The quality of life (QoL) analysis is likely to differ by region, ethnicity, and questionnaires in comparison with age-matched healthy controls. METHODS: The EORTC QLQ-C30 and QLQ-CLL17 questionnaire validated in regional languages were administered to 127 consecutive CLL and 100 age-matched, healthy controls at a single center from 2018 to 2019. RESULTS: All groups of CLL patients either on wait and watch (W&W) or on treatment had significantly impaired QoL in all functional domains including global health compared to controls (P < .0001). CLL patients had significantly higher symptom scores than controls in most domains (P < .0001, 0.03 for diarrhea). There was no difference in the QoL by age or gender. Lower socioeconomic status patients had higher financial difficulty (P = .02). Patients on CIT had the worst global health (OR 12.21 compared to patients on W&W) (P = .03). Patients on ibrutinib had less worries/fears about health and functioning than patients who were on CIT (P = .04). CONCLUSIONS: Quality of life is severely affected in CLL patients on W&W. Global health status and worries about future health and functioning were major concerns. Socioeconomic status but not age or gender impacted QoL. Patients on ibrutinib had better QoL than on CIT.
科研通智能强力驱动
Strongly Powered by AbleSci AI